J
Joelle Guilhot
Researcher at French Institute of Health and Medical Research
Publications - 159
Citations - 8016
Joelle Guilhot is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Imatinib mesylate & Myeloid leukemia. The author has an hindex of 38, co-authored 158 publications receiving 6877 citations. Previous affiliations of Joelle Guilhot include University of Poitiers.
Papers
More filters
Journal ArticleDOI
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon,Delphine Rea,Joelle Guilhot,François Guilhot,Françoise Huguet,Franck E. Nicolini,Laurence Legros,Aude Charbonnier,Agnès Guerci,Bruno Varet,Gabriel Etienne,Josy Reiffers,Philippe Rousselot +12 more
TL;DR: Imatinib discontinuation in this setting yields promising results for molecular relapse-free survival, raising the possibility that, at least in some patients, CML might be cured with tyrosine kinase inhibitors.
Journal ArticleDOI
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
Joerg Hasford,Michele Baccarani,Verena S. Hoffmann,Joelle Guilhot,Susanne Saussele,Gianantonio Rosti,François Guilhot,Kimmo Porkka,Gert J. Ossenkoppele,Doris Lindoerfer,Bengt Simonsson,Markus Pfirrmann,Rüdiger Hehlmann +12 more
TL;DR: A new prognostic score that is superior to the Sokal and Euro scores both in its prognostic ability and in its simplicity is described, which can be used to identify CML patients with significantly lower probabilities of responding to therapy and survival, thus alerting physicians to those patients who require closer observation and early intervention.
Journal ArticleDOI
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele,Johan Richter,Joelle Guilhot,Franz Gruber,Henrik Hjorth-Hansen,Antonio Almeida,Jeroen Janssen,Jiri Mayer,Perttu Koskenvesa,Panayiotis Panayiotidis,Ulla Olsson-Strömberg,Joaquin Martinez-Lopez,Philippe Rousselot,Hanne Vestergaard,Hans Ehrencrona,Veli Kairisto,Katerina Machova Polakova,Martin Müller,Satu Mustjoki,Marc G. Berger,Alice Fabarius,Wolf-Karsten Hofmann,Andreas Hochhaus,Markus Pfirrmann,Francois-Xavier Mahon,Gert J. Ossenkoppele,Maria Pagoni,Stina Söderlund,Martine Escoffre-Barbe,Gabriel Etienne,Jolanta Dengler,Françoise Huguet,Nikolas von Bubnoff,Hana Klamova,Edgar Faber,François Guilhot,Kourosh Lotfi,Delphine Rea,Tim H. Brümmendorf,Gorgine E. de Greef,Leif Stenke,Franck E. Nicolini,Laurence Legros,Andreas Burchert,Jaroslava Voglová,Aude Charbonnier,Emmanuel Gyan,Volker Kunzmann,Peter E. Westerweel +48 more
TL;DR: In this paper, a prospective, non-randomised trial was conducted at 61 European centres in 11 countries to investigate the impact of stopping TKI therapy on the survival of patients with chronic myeloid leukaemia.
Journal ArticleDOI
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Claude Preudhomme,Joelle Guilhot,Franck E. Nicolini,Agnès Guerci-Bresler,Françoise Rigal-Huguet,Frédéric Maloisel,Valérie Coiteux,Martine Gardembas,Christian Berthou,Anne Vekhoff,Delphine Rea,Eric Jourdan,Christian Allard,Alain Delmer,Philippe Rousselot,Laurence Legros,Marc G. Berger,Selim Corm,Gabriel Etienne,Catherine Roche-Lestienne,Virginie Eclache,Francois-Xavier Mahon,François Guilhot +22 more
TL;DR: As compared with other treatments, the addition of peginterferon alfa-2a to imatinib therapy resulted in significantly higher rates of molecular response in patients with chronic-phase CML.
Journal ArticleDOI
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot,Aude Charbonnier,Pascale Cony-Makhoul,Philippe Agape,Franck E. Nicolini,Bruno Varet,Martine Gardembas,Gabriel Etienne,Delphine Rea,Lydia Roy,Martine Escoffre-Barbe,Agnès Guerci-Bresler,Michel Tulliez,Stéphane Prost,Marc Spentchian,Jean Michel Cayuela,Josy Reiffers,Jean-Claude Chomel,Ali G. Turhan,Joelle Guilhot,François Guilhot,Francois-Xavier Mahon +21 more
TL;DR: Loss of MMR is a practical and safe criterion for restarting therapy in patients with CML with prolonged CMR, and should be a criterion for resuming therapy.